As of May 23, 2025, BioCryst Pharmaceuticals Inc (BCRX) reports a Current Ratio of 2.63.
Current Ratio assesses a company's ability to pay short-term debts by comparing liquid assets to liabilities, with higher ratios signaling better financial health.
Historical Trend of BioCryst Pharmaceuticals Inc's Current Ratio
Over recent years, BioCryst Pharmaceuticals Inc's Current Ratio has shown significant volatility. The table below summarizes the historical values:
| Date | Current Ratio |
|---|---|
| 2024-12-31 | 2.63 |
| 2023-12-31 | 3.31 |
| 2022-12-31 | 4.90 |
| 2021-12-31 | 5.46 |
| 2020-12-31 | 3.06 |
This slight upward trend highlights how BioCryst Pharmaceuticals Inc manages its short-term assets and liabilities over time.
Comparing BioCryst Pharmaceuticals Inc's Current Ratio to Peers
To better understand BioCryst Pharmaceuticals Inc's position, it's useful to compare its Current Ratio against industry peers. Below are selected comparisons:
| Company | Current Ratio |
|---|---|
| BioCryst Pharmaceuticals Inc (BCRX) | 2.63 |
| Morphic Holding Inc (MORF) | 28.94 |
| Celldex Therapeutics Inc (CLDX) | 18.91 |
| Xenon Pharmaceuticals Inc (XENE) | 17.85 |
| Avidity Biosciences Inc (RNA) | 15.73 |
| Scholar Rock Holding Corp (SRRK) | 9.61 |
Compared to its competitors, BioCryst Pharmaceuticals Inc's Current Ratio is about average compared to peers, reflecting balanced short-term asset management.